Associate Professor of Psychiatry, Pediatrics, and Pharmacology, Vanderbilt University School of Medicine
Jeremy Veenstra-VanderWeele uses molecular and translational neuroscience research tools in the pursuit of new treatments for autism.
On 25 June, Jeremy Veenstra-VanderWeele laid out two conceptual paths forward for developing effective autism drugs — one that focuses on the total group of people affected by autism but that might only provide modest relief, and another that could be transformative but focuses on a subset of individuals with the disorder.
Veenstra-VanderWeele is medical director of the Treatment and Research Institute for Autism Spectrum Disorders at Vanderbilt University in Nashville, Tennessee.
You can watch a complete replay of the webinar above.
Use the comments section below to submit questions we didn’t have time to discuss during the Q&A session or to pose follow-up questions for Veenstra-VanderWeele.